CMD Secures Investment from CPI Enterprises to Scale Sustainable Endotoxin Testing Platform
We’re pleased to announce that CMD has secured a £500,000 investment from CPI Enterprises, the investment arm of CPI, as part of the Innovate UK Catapult Investment Pilot. This funding marks a significant milestone in our growth and will enable us to accelerate the commercial scale-up of αBET®, our benchtop endotoxin testing platform.
Designed for use in pharmaceutical and biopharmaceutical manufacturing, αBET® offers a faster, more sustainable and user-friendly alternative to traditional endotoxin and pyrogen testing methods. The platform delivers fully quantitative results in under 30 minutes, while consuming over 90% less LAL reagent than conventional assays, supporting both operational efficiency and environmental responsibility.
We’re proud that CPI Enterprises shares our vision for transforming how the sector approaches safety and compliance testing. Jenna Bowen, CEO of CMD, explains:
“This investment marks a key milestone in our growth journey. We’re excited to expand access to αBET®, helping manufacturers improve the sustainability and efficiency of their quality control processes. By integrating with recombinant technologies and maintaining pharmacopoeial compliance, we’re proud to support the next era of innovation in injectable medicine manufacturing.”
αBET® is already being adopted by manufacturers looking to improve time-to-result, reduce reagent consumption, and increase confidence in their in-process and final product testing. The system supports a single-reagent, single-cartridge workflow, and will soon allow users to run recombinant reagents, further aligning with regulatory trends that favour non-animal-derived testing methods.
Reflecting on the investment, Frank Millar, CEO of CPI, shared:
“CMD exemplifies the type of ambitious, high-impact business we seek to back, one that combines deep scientific innovation with a strong commercial vision. With regulatory and market shifts converging in this space, CMD is well-positioned to lead the transformation of endotoxin testing, reducing reliance on animal products while improving industry efficiency.”
Originally developed from our work in infectious disease diagnostics, CMD has grown to become a specialist in pharmaceutical quality control. Alongside the αBET® instrument, CMD also operates an ISO 17025-accredited testing facility, supporting clients with routine testing, method validation, and low endotoxin recovery (LER) studies.
As the demand for biologics, advanced therapies and personalised medicines continues to rise, we remain committed to delivering next-generation endotoxin testing — faster, greener, and more accessible.